Subscribe to RSS
Download PDF
DOI: 10.1055/s-0045-1813714
Cyclophosphamide-Induced SIADH in a Breast Cancer Patient: A Serious Complication
Authors
Abstract
Cyclophosphamide is an antineoplastic agent commonly used to treat several malignancies. While it can cause a range of common side effects, including immunosuppression and alopecia, in rare instances, it has been found to cause severe hyponatremia. The probable mechanism by which it causes hyponatremia is by inducing the syndrome of inappropriate antidiuretic hormone secretion. This case report discusses the case of a 66-year-old female diagnosed with grade 3 breast cancer, who showed drastic improvement in her sodium levels with fluid restriction. Her subsequent chemotherapy regimen was changed to doxorubicin monotherapy while cyclophosphamide was omitted, to which she responded favorably without any hyponatremia. Early recognition and prompt treatment of this life-threatening complication are important.
Financial Disclosure
None.
Publication History
Article published online:
02 December 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Ogino MH, Tadi P. Cyclophosphamide. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2025. . Accessed November 10, 2025 at: http://www.ncbi.nlm.nih.gov/books/NBK553087/
- 2 Steinman R, Schwab SE, Munir KM. Cyclophosphamide-induced hyponatremia in a patient with diabetes insipidus. J Endocrinol Metab 2015; 5 (06) 337-339
- 3 Campbell DM, Atkinson A, Gillis D, Sochett EB. Cyclophosphamide and water retention: mechanism revisited. J Pediatr Endocrinol Metab 2000; 13 (06) 673-675
- 4 Harlow PJ, DeClerck YA, Shore NA, Ortega JA, Carranza A, Heuser E. A fatal case of inappropriate ADH secretion induced by cyclophosphamide therapy. Cancer 1979; 44 (03) 896-898
- 5 Bruining DM, van Roon EN, de Graaf H, Hoogendoorn M. Cyclophosphamide-induced symptomatic hyponatraemia. Neth J Med 2011; 69 (04) 192-195
- 6 Jayachandran NV, Chandrasekhara PKS, Thomas J, Agrawal S, Narsimulu G. Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis. Rheumatology (Oxford) 2009; 48 (01) 89-90
- 7 Natarajan K, Srinivas CR, Jayachandran K, Ramanathan RMPL. Cyclophosphamide-induced syndrome of inappropriate antidiuretic hormone secretion. Indian J Dermatol Venereol Leprol 2009; 75 (06) 629-630
- 8 Esposito P, Domenech MV, Serpieri N. et al. Severe cyclophosphamide-related hyponatremia in a patient with acute glomerulonephritis. World J Nephrol 2017; 6 (04) 217-220
- 9 Webberley MJ, Murray JA. Life-threatening acute hyponatraemia induced by low dose cyclophosphamide and indomethacin. Postgrad Med J 1989; 65 (770) 950-952
- 10 Hwang SB, Lee HY, Kim HY, Lee ES, Bae JW. Life-threatening acute hyponatremia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer. J Breast Cancer 2011; 14 (04) 345-348
- 11 Geng C, Tang P, Zhang Y, Gao W. Hyponatremia induced by low-dose cyclophosphamide in two patients with breast cancer. Breast J 2014; 20 (04) 442-443
- 12 Baker M, Markman M, Niu J. Cyclophosphamide-induced severe acute hyponatremic encephalopathy in patients with breast cancer: report of two cases. Case Rep Oncol 2014; 7 (02) 550-554